Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Times cited: 25
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
Times cited: 69
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
Times cited: 72